The Effects of Corneal Collagen Cross-linking

Rush Eye Associates

Status and phase: Enrolling; Phase 3

Conditions: Corneal Ectasia Disorders Including Keratoconus

Treatments: Drug: CXL

Study type: Interventional

Funder types: Other

Identifiers

NCT01708538

Rush CXL

Details and patient eligibility

About

The corneal collagen cross-linking treatment has been used with increasing success to treat corneal dystrophies such as "keratoconus." Recent advances have allowed different techniques for performing this cross-linking treatment. This study investigates the effects of corneal cross-linking using different surgical techniques.

Enrollment: 30 estimated patients

Sex: All

Ages: 10 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

Exclusion criteria

• Unwilling or unable to participate in trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

30 participants in 2 patient groups

Epithelium on

Active Comparator group

Description:

Epi not removed during CXL treatment

Treatment:

Drug: CXL

Epithelium off

Active Comparator group

Description:

Epi removed before CXL treatment

Treatment:

Drug: CXL